

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV323461471US, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: March 31, 2005

Signature: Jean Bove

(Jean Bove)

Docket No.: CLFR:141USD2  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Re Patent Application of:  
J. F. Crawford

Application No.: 10/696,334

Confirmation No.: 8097

Filed: October 29, 2003

Art Unit: 1651

For: ASSESSMENT OF INTRACELLULAR  
CYSTEINE AND GLUTATHIONE  
CONCENTRATIONS

Examiner: R. J. Gitomer

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed more than three months after the U.S. filing date, OR more than three months after the date of entry of the national stage of a PCT application, AND after the mailing date of the first Office Action on the merits, whichever occurs first, but before the mailing date of a Final Office Action or Notice of Allowance (37 CFR 1.97(c)).

A copy of "Other Art" citations on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR

04/05/2005 MBERHE 00000099 500337 10696334

01 FC:1806 180.00 DA

04/05/2005 MBERHE 00000108 500337 10696334  
01 FC:1806 180.00 DA


1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

Please charge the our Deposit Account No. 50-0337 in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p) is enclosed. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-0337, under Order No. AO-CLFR:141USD2. A duplicate copy of this paper is enclosed.

Dated: March 31, 2005

Respectfully submitted,

By 

Miles Yamanaka

Registration No.: 45,665

FULBRIGHT & JAWORSKI L.L.P.

865 S. Figueroa St., Suite 2800

Los Angeles, CA 90017

(213) 892-9212

(213) 680-4518 (Facsimile)

Attorney for Applicant

Form PTO-1449 (modified)

Atty. Docket No.

CLFR:141USD2

Serial No.

10/696,334

Office of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Crawford

Filing Date:

10/29/03

Group:

1651

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
*	A1	4,499,064	2/12/85	Shive	435	14	5/6/83
*	A2	4,927,762	5/22/90	Darfler	435	387	11/30/88
	A3	5,171,885	12/15/92	Griffith	562	556	6/19/91
	A4	5,290,571	3/1/94	Bounous <i>et al.</i>	424	535	10/4/89
	A5	5,405,772	4/11/95	Ponting	435	378	6/18/93
	A6	5,326,699	7/5/94	Torishima <i>et al.</i>	435	384	11/14/93
*	A7	5,607,974	3/4/97	Droge <i>et al.</i>	514	562	1/10/94
*	A8	5,985,665	11/16/99	Crawford <i>et al.</i>	435	404	6/19/96
*	A9	6,262,019	7/17/01	Keller <i>et al.</i>	514	2	4/29/99
*	A10	6,514,955	2/4/03	Van Dyke	514	171	6/7/95
*	A11	6,709,835	3/23/04	Crawford	435	25	12/13/01
*	A12	20020136763	11/26/02	Demopoulos <i>et al.</i>	424	451	2/25/02

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1						

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
*	C1	Fidelus <i>et al.</i> , "Modulation of intracellular glutathione concentrations alters lymphocyte activation and proliferation," <i>Exp. Cell Res.</i> , 170:269-275, 1987.
*	C2	Hamilos <i>et al.</i> , "Lymphocyte proliferation in glutathione-depleted lymphocytes: direct relationship between glutathione availability and the proliferative response," <i>Immunopharmacology</i> , 18:223-235, 1989.

CLFR\_141USD2 1449.DOC

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. CLFR:141USD2	Serial No. 10/696,334
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Crawford	
		Filing Date: 10/29/03	Group: 1651
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
*	C3	Messina <i>et al.</i> , "Effects of 2-mercaptoethanol and buthionine sulfoximine on cystine metabolism by and proliferation of mitogen-stimulated human and mouse lymphocytes," <i>Int. J. Immunopharmacology</i> , 14:1221-1234, 1992.

CLFR\_141USD2 1449.DOC

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.